89.57 % to Target, Piper Jaffray Reaffirms ‘”Buy”’ Rating on Aimmune Therapeutics (AIMT) Shares Today

March 18, 2018 - By Marguerite Chambers

 89.57 % to Target, Piper Jaffray Reaffirms ‘

Aimmune Therapeutics (AIMT) Rating Reaffirmed

Recently, In a research note sent to investors on 5 December, Aimmune Therapeutics (AIMT) shares have had their “Buy” Rating restate by stock research analysts at Piper Jaffray, who currently has a $60.0 TP on firm. This target by Piper Jaffray gives the possibile upside of 89.57 % from the stock close price.

Aimmune Therapeutics, Inc. (NASDAQ:AIMT) Ratings Coverage

Among 9 analysts covering Aimmune Therap… (AIMT), 9 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Aimmune Therap… has $80.0 highest and $30.0 lowest target. $58.13’s average target is 83.67% above currents $31.65 stock price. Aimmune Therap… had 31 analyst reports since March 7, 2016 according to SRatingsIntel. On Monday, July 24 the stock rating was maintained by Wedbush with “Buy”. The stock of Aimmune Therapeutics, Inc. (NASDAQ:AIMT) has “Buy” rating given on Wednesday, June 14 by Wedbush. The firm earned “Buy” rating on Tuesday, February 27 by Credit Suisse. Roth Capital maintained it with “Buy” rating and $80.0 target in Monday, March 5 report. As per Monday, November 20, the company rating was initiated by Roth Capital. The firm earned “Buy” rating on Monday, October 23 by Wedbush. Wedbush maintained Aimmune Therapeutics, Inc. (NASDAQ:AIMT) on Friday, December 1 with “Buy” rating. Piper Jaffray maintained it with “Buy” rating and $3800 target in Thursday, July 27 report. As per Monday, February 12, the company rating was maintained by Wedbush. The firm earned “Buy” rating on Monday, October 23 by Credit Suisse.

The stock decreased 2.01% or $0.65 during the last trading session, reaching $31.65. About 2.03 million shares traded or 115.90% up from the average. Aimmune Therapeutics, Inc. (AIMT) has risen 32.49% since March 18, 2017 and is uptrending. It has outperformed by 15.79% the S&P500.

Analysts await Aimmune Therapeutics, Inc. (NASDAQ:AIMT) to report earnings on May, 14. They expect $-0.67 EPS, down 28.85 % or $0.15 from last year’s $-0.52 per share. After $-0.81 actual EPS reported by Aimmune Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -17.28 % EPS growth.

Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies in the United States and Europe. The company has market cap of $1.83 billion. The Company’s lead Characterized Oral Desensitization ImmunoTherapy product candidate is AR101, an investigational biologic for the treatment of patients with peanut allergy. It currently has negative earnings. Aimmune Therapeutics, Inc. has strategic collaboration with an affiliate of Nestle Health Science US Holdings, Inc. for the advancement of food allergy therapeutics.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.